防风通圣散对非酒精性脂肪性肝病模型大鼠肝细胞水通道蛋白9表达的影响
详细信息 查看官网全文
- 英文论文题名：Effect of Fangfeng Tongsheng Powder on the Expression of AQP-9 in Nonalcoholic fatty liver rats
- 论文作者：彭昭宣 ; 米绍平 ; 朱晓宁 ; 汪静
- 英文论文作者：Peng Zhao-xuan ; Mi Shao-ping ; Zhu Xiao-ning ; Wang Jing ; Department of Hepatobiliary Diseases ; Affiliated Chinese Medicine Hospital ; Southwest Medical University
- 年：2016
- 作者机构：西南医科大学附属中医医院肝胆病科;
- 论文关键词：防风通圣散 ; 非酒精性脂肪性肝病 ; AQP-9
- 英文论文关键词：Fangfeng Tongsheng Powder ; nonalcoholic fatty liver disease ; AQP-9
- 会议召开时间：2016-12-01
- 会议录名称：中国医师进修论文选编
- 语种：中文
- 分类号：R285.5;R-332
- 学会代码：BCLK
- 会议名称：2016年12月中国医师进修学术交流会
- 会议地点：中国北京
- 主办单位：中国医师进修编委会
- 学会名称：百川利康（北京）国际医学研究院
- 页数：5
- 文件大小：788k
- 原文格式：D
- 会议级别：全国
摘要
目的:建立非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)大鼠模型,观察防风通圣散对NAFLD大鼠血清的生化指标(AST、ALT、TG、TC)的干预作用,以及对水甘油通道蛋白9(AQP-9)表达水平的变化,探讨防风通圣散干预NAFLD可能的作用机制。方法:取成年SD雄性大鼠60只,完全随机分为5个组,正常、模型对照组;防风通圣散高、中、低剂量治疗组,每组各12只,治疗组剂量分别为16,12,6 g·kg~(-1) ig qd。正常和模型对照组予以同等剂量生理盐水。于造模第6、8、10周末,取大鼠肝脏HE染色判定造模是否成功。造模成功后,第10周后开始给予防风通圣散高、中、低剂量干预2周,然后测定AST、ALT、TG、TC,处死所有大鼠,取肝脏进行HE染色1,并检测大鼠肝脏细胞AQP-9mRNA的表达水平。结果:与正常对照组相比较,模型对照组大鼠血清AST、ALT、TG、TC指标以及肝细胞脂变程度均有明显的增高、加重(P<0.01)。与模型对照组比较,防风通圣散高、中、低剂量组大鼠血清AST、ALT、TG、TC指标降低,肝细胞脂变程度减轻,均有统计学差异(P<0.05)。中药中剂量组与高剂量组均较模型对照组AQP-9表达水平低(P<0.05)。结论:1、防风通圣散可以降低NAFLD大鼠模型中的AQP-9表达的水平;2、防风通圣散能减轻NAFLD大鼠肝细胞脂变性程度,改善肝功能,调节脂质水平;3、本实验推测通过抑制或阻断AQP-9表达可能是防风通圣散干预NAFLD的作用机制之一。
Objective: Through the establishment of nonalcoholic fatty liver disease(NAFLD) rat model, to observe Fangfeng Tongsheng Powder that effects on them, such as serum biochemical levels(AST、ALT、TG、TC)in rats, AQP-9 expression, in order to Study the effect of Fangfeng Tongsheng Powder treatment of NAFLD mechanism. Method:60 SD male rats were randomly divided into Normal control group with 12 rats, Model control group with 12 rats,Fangfeng Tongsheng Powder High dose group(16 g·kg-1), Middle dose group(12 g·kg-1),and Low dose group(6 g·kg-1)each with 12 rats. Model control group and Normal control group were given the same dose of 0.9%NS. At the end of 6,8,10 th week, we were hematoxylin-eosin staining to determine whether successful modeling. After the modeling,drugs intervened two weeks for High、Middle and Low dose group, then we observed pathological changes in liver tissue and blood biochemical parameters AST、ALT、TG、TC, and all rats were dissected at the end. The liver tissues were detected the expression of AQP-9 m RNA in rat liver. Result:In Normal control group compared with Model control group, serum AST、ALT、TG、TC level, and degree of hepatic steatosis showed significantly increased(P<0.01). In Model control group compared with Low、Middle and High dose treatment groups of Fangfeng Tongsheng Powder, the serum AST、ALT、TG、TC level, and degree of hepatic steatosis had statistically significant difference(P<0.05). Middle dose and High dose were compared with Model control group, the lower levels of AQP-9 expression than Model control group(P<0.05).Conclusion: 1、Fangfeng Tongsheng Powder can reduce the expression level of AQP-9 in NAFLD rat liver;2、Fangfeng Tongsheng Powder will reduce nonalcoholic fatty liver rats liver fatty degeneration, regulate lipid metabolism disorders, improve liver function to a certain extent;3、The experiment suggests that inhibition of the AQP-9 expression perhaps one of the mechanisms for the treatment of NAFLD.
Objective: Through the establishment of nonalcoholic fatty liver disease(NAFLD) rat model, to observe Fangfeng Tongsheng Powder that effects on them, such as serum biochemical levels(AST、ALT、TG、TC)in rats, AQP-9 expression, in order to Study the effect of Fangfeng Tongsheng Powder treatment of NAFLD mechanism. Method:60 SD male rats were randomly divided into Normal control group with 12 rats, Model control group with 12 rats,Fangfeng Tongsheng Powder High dose group(16 g·kg-1), Middle dose group(12 g·kg-1),and Low dose group(6 g·kg-1)each with 12 rats. Model control group and Normal control group were given the same dose of 0.9%NS. At the end of 6,8,10 th week, we were hematoxylin-eosin staining to determine whether successful modeling. After the modeling,drugs intervened two weeks for High、Middle and Low dose group, then we observed pathological changes in liver tissue and blood biochemical parameters AST、ALT、TG、TC, and all rats were dissected at the end. The liver tissues were detected the expression of AQP-9 m RNA in rat liver. Result:In Normal control group compared with Model control group, serum AST、ALT、TG、TC level, and degree of hepatic steatosis showed significantly increased(P<0.01). In Model control group compared with Low、Middle and High dose treatment groups of Fangfeng Tongsheng Powder, the serum AST、ALT、TG、TC level, and degree of hepatic steatosis had statistically significant difference(P<0.05). Middle dose and High dose were compared with Model control group, the lower levels of AQP-9 expression than Model control group(P<0.05).Conclusion: 1、Fangfeng Tongsheng Powder can reduce the expression level of AQP-9 in NAFLD rat liver;2、Fangfeng Tongsheng Powder will reduce nonalcoholic fatty liver rats liver fatty degeneration, regulate lipid metabolism disorders, improve liver function to a certain extent;3、The experiment suggests that inhibition of the AQP-9 expression perhaps one of the mechanisms for the treatment of NAFLD.
引文
[1]Chitturi S,Farrei G C.Etiopathogenesis of non-alcoholic steatohe-patitis[J].Semin-Liver Dis,2001,21(1):27-41
[2]董姝,刘平,孙明瑜.非酒精性脂肪性肝病发病机制--“二次打击”学说研究进展[J].临床肝胆病杂志,2012,28(7):551-553.
[3]彭昭宣.防风通圣散对非酒精性脂肪肝大鼠肝细胞AQP-9表达的影响[D].泸州医学院,2014.
[4]Pietrement C,Da Silva N,Silherstein C,et a1.Role of NHERF1,CFTR and c AMP in the regulation of aquaporin9[J].JBiol Chem,2007,283(35):98739.
[5]Fossdal G,Vik-Mo EO,Sandberg C,et al.Aqp 9 and brain tumour cells.Scientific World Journal,2012,2012:915176.
[6]冉吕,梅浙川.水通道蛋白9与消化系统疾病[J].检验医学与临床,2013,08:1000-1002.
[7]赵静,李婧,杨旭,杜继臣.水通道蛋白9的研究进展[J].中华临床医师杂志(电子版),2013,14:6585-6587.)
[8]Carbrey J M,Gorelick-Feldman D A,Kozono D A,et a1Aquaglycero-pofin AQP9:solute permeation and metabolic control of expression in liver[J].Proc Natl Acad Sci USA,2003,100(5):2945-2950.
[9]Rojek A M,Skowronski M T,Fuchtbauer E M,et a1.Defective glycerol metabolism in aquaporin9(AQP9)knockout mice[J].Proc Natl Acad Sci USA,2007,104(8):3609-3614.
[10]赵丰莹,梅浙川.水通道蛋白9在培养肝细胞脂肪变性模型中的表达及意义[J].重庆医科大学学报,2008,33(8):934-937.
[11]朱晓宁,米绍平,汪静.水通道蛋白9与非酒精性脂肪肝的研究进展[J].泸州医学院学报,2013,36(2),201-202.
[12]王宏伟.防风通圣散[J].开卷有益-求医问药,2015,04:55.
[13]陈芳,刘莉,杨欣.防风通圣颗粒联合硫普罗宁治疗非乙醇性脂肪肝临床观察[J].中国临床药学杂志,2010,19(3):167-169.
[14]南万青,南万年.防风通圣散临床应用4则[J].山西中医,2010,26(4):33.
[15]陈奇主编.中药药理研究方法学[M].北京:人民卫生出版社,1993:33-34.
[16]陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2009:435-437.
[17]王建清,王魁亮.代谢综合征从痰瘀论治探析[J].新疆医药,2007,25(3).
[18]刘燕玲,陈立华.浅谈脂肪肝的中医药治疗[J].北京中医药大学学报,1995;18(5):54.
[19]李干,张桂英,李新华.482例脂肪肝患者临床分析[J].中国现代医学杂志,2002;12(9):5.
[20]彭昭宣,汪静.防风通圣散治疗脂肪肝的研究进展[J].内蒙古中医药,2013,13:134-135.
[21]赵丰莹.AQP9在非酒精性脂肪肝中作用机制的研究[D].重庆医科大学,2008.
[22]朱晓宁,汪静,米绍平,彭昭宣.祛痰活血汤对非酒精性脂肪性肝病模型大鼠水通道蛋白9表达的影响[J].中国实验方剂学杂志,2014,23:160-164.
[2]董姝,刘平,孙明瑜.非酒精性脂肪性肝病发病机制--“二次打击”学说研究进展[J].临床肝胆病杂志,2012,28(7):551-553.
[3]彭昭宣.防风通圣散对非酒精性脂肪肝大鼠肝细胞AQP-9表达的影响[D].泸州医学院,2014.
[4]Pietrement C,Da Silva N,Silherstein C,et a1.Role of NHERF1,CFTR and c AMP in the regulation of aquaporin9[J].JBiol Chem,2007,283(35):98739.
[5]Fossdal G,Vik-Mo EO,Sandberg C,et al.Aqp 9 and brain tumour cells.Scientific World Journal,2012,2012:915176.
[6]冉吕,梅浙川.水通道蛋白9与消化系统疾病[J].检验医学与临床,2013,08:1000-1002.
[7]赵静,李婧,杨旭,杜继臣.水通道蛋白9的研究进展[J].中华临床医师杂志(电子版),2013,14:6585-6587.)
[8]Carbrey J M,Gorelick-Feldman D A,Kozono D A,et a1Aquaglycero-pofin AQP9:solute permeation and metabolic control of expression in liver[J].Proc Natl Acad Sci USA,2003,100(5):2945-2950.
[9]Rojek A M,Skowronski M T,Fuchtbauer E M,et a1.Defective glycerol metabolism in aquaporin9(AQP9)knockout mice[J].Proc Natl Acad Sci USA,2007,104(8):3609-3614.
[10]赵丰莹,梅浙川.水通道蛋白9在培养肝细胞脂肪变性模型中的表达及意义[J].重庆医科大学学报,2008,33(8):934-937.
[11]朱晓宁,米绍平,汪静.水通道蛋白9与非酒精性脂肪肝的研究进展[J].泸州医学院学报,2013,36(2),201-202.
[12]王宏伟.防风通圣散[J].开卷有益-求医问药,2015,04:55.
[13]陈芳,刘莉,杨欣.防风通圣颗粒联合硫普罗宁治疗非乙醇性脂肪肝临床观察[J].中国临床药学杂志,2010,19(3):167-169.
[14]南万青,南万年.防风通圣散临床应用4则[J].山西中医,2010,26(4):33.
[15]陈奇主编.中药药理研究方法学[M].北京:人民卫生出版社,1993:33-34.
[16]陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2009:435-437.
[17]王建清,王魁亮.代谢综合征从痰瘀论治探析[J].新疆医药,2007,25(3).
[18]刘燕玲,陈立华.浅谈脂肪肝的中医药治疗[J].北京中医药大学学报,1995;18(5):54.
[19]李干,张桂英,李新华.482例脂肪肝患者临床分析[J].中国现代医学杂志,2002;12(9):5.
[20]彭昭宣,汪静.防风通圣散治疗脂肪肝的研究进展[J].内蒙古中医药,2013,13:134-135.
[21]赵丰莹.AQP9在非酒精性脂肪肝中作用机制的研究[D].重庆医科大学,2008.
[22]朱晓宁,汪静,米绍平,彭昭宣.祛痰活血汤对非酒精性脂肪性肝病模型大鼠水通道蛋白9表达的影响[J].中国实验方剂学杂志,2014,23:160-164.